Eprenetapopt plus azacitidine fails to meet primary endpoint for use in TP53 mutant myelodysplastic syndromes

In a phase 3 study, the combination treatment appeared to demonstrate a higher complete remission rate than azacitidine alone, however it was not statistically significant. Eprenetapopt is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein.

Source:

Biospace Inc.